
Free Daily Podcast Summary
by Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes.
The most recent episodes — sign up to get AI-powered summaries of each one.
Join us as we discussed the practice changing/informing studies presented at ESMO 2026. In this episode, we welcomed Dr. Javier Cortés, from Spain to discuss 4 key studies that are shaping the future of breast cancer treatment. Episode Highlights: NATALEE: An update on adjuvant ribociclib for T2N0 with high-risk features and node-positive disease, including its impact on overall survival (OS) and distant disease-free survival (DDFS) postMONARCH: Insights into the use of abemaciclib after prior CDK4/6 inhibitors in metastatic hormone receptor–positive breast cancer, focusing on progression-free survival (PFS) and OS outcomes TROPION-Breast02: A look at the TNBC, highlighting the efficacy of datopotamab deruxtecan (Dato-DXd) in patients with central nervous system (CNS) metastasis INSPIRE-LM: Exploring the promising results of intrathecal trastuzumab and pertuzumab for patients with leptomeningeal disease in HER2-positive metastatic breast cancer Tune in for an in-depth discussion on the latest advancements in breast cancer treatment and how these findings can be integrated into clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #BreastCancer, #ESMO2026, #CDK4-6i, #ADC, #OncologyBrothers
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the complex world of neuroendocrine tumors (NETs) with renowned specialist Dr. Pamela Kunz, from Yale School of Medicine. Join us as we explore: The heterogeneous nature of neuroendocrine tumors, including differences in grade, origin, and functionality Diagnostic workups and the role of imaging, including the use of ⁶⁸Ga-DOTATATE positron emission tomography (PET) scans Treatment algorithms for both localized and metastatic NETs, focusing on somatostatin analogs, ¹⁷⁷Lu-DOTATATE, and other therapeutic options The importance of shared decision-making in treatment approaches, especially for asymptomatic patients Monitoring strategies and the evolving role of biomarkers like chromogranin A Insights into high-grade neuroendocrine tumors and the potential for immunotherapy Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the current treatment landscape for neuroendocrine tumors. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #NeuroendocrineTumors, #NETs, #DOTATATE, #OncologyBrothers
In this segment of the treatment algorithms, we focused on rectal cancer treatment landscape with Dr. Nina Sanford, a radiation oncologist, and Dr. Madhu Eluri, MD, a medical oncologist. In this episode, we discussed: The recent approval of dostarlimab for MSI-high rectal cancer and its implications for treatment The importance of a multidisciplinary approach in managing stage II and III rectal cancer The debate between total neoadjuvant treatment (TNT) versus the PROSPECT trial approach The role of chemotherapy, radiation, and surgery in various risk categories of rectal cancer How to monitor patients post-treatment and the significance of circulating tumor DNA (ctDNA) in decision-making Insights into the management of metastatic rectal cancer and the potential for organ preservation Tune in for a comprehensive discussion that emphasizes the importance of biomarker-driven care and the evolving landscape of rectal cancer treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #RectalCancer, #MultiD, #MSI-H, #TNT, #OncologyBrothers
In this episode of the Oncology Brothers podcast, we dived deep into the world of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Joined by Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins School of Medicine, as we explored the intricacies of EGFR exon 20 insertions, the third most common mutation, and other rare mutations such as G719X, S768I, and L861Q. Key topics discussed include: The importance of broad-based next-generation sequencing (NGS) testing for identifying EGFR mutations Current treatment options for exon 20 insertions, including the combination of amivantamab and chemotherapy, and the promising data surrounding sunvozertinib The challenges and considerations in treating patients with central nervous system (CNS) metastases and the role of systemic treatments versus localized therapies Insights into the sequencing of treatments for rare EGFR mutations and the potential of datopotamab deruxtecan (Dato-DXd) in refractory settings Join us for an informative discussion that sheds light on the evolving landscape of targeted therapies for EGFR-mutated NSCLC. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes! #EGFRmNSCLC, #Exon20Insertion, #G719X, #S768I, #L861Q, #OncologyBrothers
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial. Join us as we explored: The evolution of treatment standards for MIBC over the past 2 years Key insights from the VOLGA trial, including study design, findings, and clinical implications The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen The balance between overtreatment and undertreatment in patient care The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial
We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib. Key topics covered include: The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma The shift from single-agent osimertinib to combination therapies and the implications for patient care Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations The importance of shared decision-making in oncology Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations. #EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers
Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment. Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice: DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC) SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers
Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies. Join us as we discussed: HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and surgery CheckMate 8HW: Insights into the superiority of dual checkpoint inhibition over single-agent immunotherapy for MSI-high metastatic colorectal cancer HARMONi-GI1: A look at ivonescimab combined with chemotherapy in biliary tract cancer, showing promising results despite being a China-only study Tune in for expert insights from GI medical oncologists Drs. Eric Van Cutsem and Manish Shah, as they share their thoughts on these pivotal studies and their impact on clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers podcast! #GIOncology, #ESMO2026, #UpperGI, #Colorectal, #OncologyBrothers
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

INTERLUDE: Cancer Stories with Dr. Teplinsky
Eleonora Teplinsky

Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.

The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.

Core IM | Internal Medicine Podcast
A podcast exploring internal medicine through clinical reasoning, management decisions, and practical teaching points.

Thrive Through and Beyond Cancer
Season Johnson

Frankly Speaking About Family Medicine
Discusses current topics and developments in primary care and family medicine.

The Antisocial Doctors Podcast
Sonia Singh MD & Rebecca Berens MD

Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.

The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.

ICU Ed and Todd-Cast
Eddie and Todd

Health Matters
NewYork-Presbyterian

The Dr. Hyman Show
Explores root causes of chronic disease and promotes functional medicine, nutrition, and preventive health through expert discussions.
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Oncology Brothers: Practice-Changing Cancer Discussions in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Oncology Brothers: Practice-Changing Cancer Discussions as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Oncology Brothers.
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
Oncology Brothers: Practice-Changing Cancer Discussions publishes every few days. Our AI generates a summary within hours of each new episode.
Oncology Brothers: Practice-Changing Cancer Discussions covers topics including Medicine, Fitness, Health & Fitness. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.